Cargando…

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases: An Observational Study

Epidermal growth factor receptor (EGFR) activating mutations are a predictor of tyrosine kinase inhibitor effectiveness in the treatment of non–small-cell lung cancer (NSCLC). The objective of this study is to build a model for predicting the EGFR mutation status of brain metastasis in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Nan, Wang, Ge, Wu, Yu-Hao, Chen, Shi-Feng, Liu, Guo-Dong, Chen, Chuan, Wang, Dong, He, Zhong-Shi, Yang, Xue-Qin, He, Yong, Xiao, Hua-Liang, Huang, Ding-De, Xiong, Kun-Lin, Wu, Yan, Huang, Ming, Yang, Zhen-Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602717/ https://www.ncbi.nlm.nih.gov/pubmed/25654374 http://dx.doi.org/10.1097/MD.0000000000000375

Ejemplares similares

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis
por: Lan, Bo, et al.
Publicado: (2021)

Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients
por: Tang, Cuiping, et al.
Publicado: (2022)

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis
por: Hong, Xiaohua, et al.
Publicado: (2022)

Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
por: Lin, Chia-Ying, et al.
Publicado: (2019)

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution
por: He, Xiaobo, et al.
Publicado: (2016)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

Prognostic potential of miR-144 in various cancers: A meta-analysis
por: Jia, Chong-Yang, et al.
Publicado: (2022)

Penile metastases from primary lung cancer: Case report and literature review
por: Guo, Ling-Chuan, et al.
Publicado: (2017)

Complete response of radioresistant brain metastases from non-small cell lung cancer with temozolomide: A case report and literature review
por: Yang, Yi, et al.
Publicado: (2020)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature
por: Guo, Qiang, et al.
Publicado: (2023)

Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis
por: He, Canfeng, et al.
Publicado: (2021)

A network meta-analysis: The best Yiqi Fuzheng Chinese herbal injections for use based on the NP regimen to treat NSCLC
por: Luo, Huiyan, et al.
Publicado: (2020)

Isolated splenic metastases from rectal carcinoma 5 years after surgery: Case report
por: Xu, Jie, et al.
Publicado: (2023)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Mao, Chen, et al.
Publicado: (2015)

High Incidence of EGFR Mutations in Pneumonic-Type Non-Small Cell Lung Cancer
por: Liu, Jun, et al.
Publicado: (2015)

An upper cervical cord compression secondary to occult follicular thyroid carcinoma metastases successfully treated with multiple radioiodine therapies: A clinical case report
por: Dong, Ping, et al.
Publicado: (2017)

(18)F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer
por: Guan, Jian, et al.
Publicado: (2016)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report
por: Bie, Yanan, et al.
Publicado: (2021)

Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases
por: Chou, Wen-Chi, et al.
Publicado: (2015)

Construction of a nomogram to predict the prognosis of non-small-cell lung cancer with brain metastases
por: Huang, Zhangheng, et al.
Publicado: (2020)

Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports
por: Lai, Lin, et al.
Publicado: (2021)

Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
por: Qi, Nan, et al.
Publicado: (2016)

Construction of a 5 immune-related lncRNA-based prognostic model of NSCLC via bioinformatics
por: Huang, Ya-jie, et al.
Publicado: (2021)

Musashi1 expression is negatively correlated with numb expression in brain metastases
por: Dong, Yalan, et al.
Publicado: (2020)

Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis
por: Dong, Dong, et al.
Publicado: (2022)

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
por: Yang, Jiaying, et al.
Publicado: (2016)

Recent death early warning value of ECG changes in patients with NSCLC
por: Liu, Qiong, et al.
Publicado: (2023)

Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma
por: Ju, Qing, et al.
Publicado: (2021)

Brain metastases from esophageal cancer: A case report
por: Qie, Shuai, et al.
Publicado: (2020)

Clinical characteristics and establishment of a 2-year-OS predictive model of EGFR mutation-positive patients with pleural invasion of lung adenocarcinoma
por: Kong, Qing, et al.
Publicado: (2023)

Lung adenocarcinoma with EGFR gene mutation metastatic to the uterine cervix: A case report
por: Wang, Yong, et al.
Publicado: (2020)

Definitive local therapy for extracranial single-organ oligorecurrent non-small-cell lung cancer: A single institutional retrospective study
por: Jin, Jia-Nan, et al.
Publicado: (2022)

Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report
por: Wang, Guannan, et al.
Publicado: (2019)

Recurrent spinal primitive neuroectodermal tumor with brain and bone metastases: A case report
por: Chen, Frank, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_47031kv4pq3mibs3jd0jlosnh6